Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

MYSTIC: Developing biomarkers for metastatic NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.19
Views: 620
Rating:

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Prof Solange Peters speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the MYSTIC trial that aims to evaluate the opportunity of administering front-line immunotherapy in patients with metastatic NSCLC.

This three-arm randomised trial consisted of administering durvalumab, with or without tremelimumab versus platinum-based chemotherapy.

Prof Peters discusses why the primary endpoint did not reach statistical significance, despite achieving a clinically meaningful result that supported the use of durvalumab compared to chemotherapy.

Prof Peters also explains the role of the 'tumour mutational burden' as a clinical biomarker for this disease type in the future.
 

Related videos

follow us

CML Life Banner


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation